Sigyn Therapeutics, Inc. (OTCQB: SIGY) has released a note from CEO Jim Joyce detailing the potential of CardioDialysis, a next-generation blood purification technology designed to reduce major adverse cardiovascular events (MACE). Cardiovascular disease remains the leading cause of death worldwide, and current therapies such as statins reduce MACE by only about 25%. In contrast, Lipoprotein Apheresis devices that filter LDL-C and Lipoprotein(a) from the bloodstream can reduce MACE by 75-95%, according to the American Heart Association. However, the complexity of these systems has limited their use to specialized centers.
CardioDialysis aims to overcome these limitations by integrating plasma separation and therapeutic adsorption into a single device that can be deployed on dialysis machines already present in over 5,000 hospitals and 7,500 dialysis clinics in the United States. Unlike existing systems like the Kaneka LIPOSORBER, which requires multiple components and specialized centers, CardioDialysis processes the bloodstream with greater efficiency and does not require replacement fluids or additional pumps. The technology targets a broader range of cardiovascular disease targets and enables continuous clearance of inflammatory and pathogenic molecules from the entire bloodstream.
Jim Joyce, inventor and CEO, emphasized that with 15-20% of MACE resulting in death, successful clinical advancement of CardioDialysis could save thousands of lives each year. The device is positioned within the emerging field of subtractive medicine, with therapeutic opportunities extending beyond cardiovascular disease to include sepsis, viral infections, and neuroinflammatory disorders. Sigyn's pipeline also includes ImmunePrep, ChemoPrep, and ChemoPure technologies for cancer treatment. For more information, visit SigynTherapeutics.com.
